Imami, Ali S; O'Donovan, Sinead M; Creeden, Justin F; Wu, Xiaojun; Eby, Hunter; McCullumsmith, Cheryl B; Uvnäs-Moberg, Kerstin; McCullumsmith, Rob E; Andari, Elissar
description
The Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) has caused a worldwide pandemic, infecting over 16 million people worldwide with a significant mortality rate. However, there is no current FDA approved drug that treats COVID-19. Damage to T lymphocytes along with the cytokine storm are important factors that lead to exacerbation of clinical cases. Here, we are proposing intravenous oxytocin (OXT) as a candidate for adjunctive therapy for COVID-19. OXT has anti-inflammatory and pro-immune adaptive functions. Using the Library of Integrated Network-Based Cellular Signatures (LINCS), we used the transcriptomic signature for carbetocin, an OXT agonist, and compared it to gene knockdown signatures of inflammatory (such as interleukin IL-1β and IL-6) and pro-immune markers (including T cell and macrophage cell markers like CD40 and ARG1). We found that carbetocin's transcriptomic signature has a pattern of concordance with inflammation and immune marker knockdown signatures that are consistent with reduction of inflammation and promotion and sustaining of immune response. This suggests that carbetocin may have potent effects in modulating inflammation, attenuating T-cell inhibition and enhancing T-cell activation. Our results also suggest that carbetocin is more effective at inducing immune cell responses than either lopinavir or hydroxychloroquine, both of which have been explored for the treatment of COVID-19. Keywords: COVID19, Oxytocin, Immune, LINCS, Transcriptomic Signature.
